GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Apyx Medical Corp (NAS:APYX) » Definitions » Cash Flow from Operations

Apyx Medical (Apyx Medical) Cash Flow from Operations : $-9.71 Mil (TTM As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Apyx Medical Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2024, Apyx Medical's Net Income From Continuing Operations was $-7.59 Mil. Its Depreciation, Depletion and Amortization was $0.16 Mil. Its Change In Working Capital was $-0.32 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $1.13 Mil. And its Cash Flow from Others was $0.28 Mil. In all, Apyx Medical's Cash Flow from Operations for the three months ended in Mar. 2024 was $-6.34 Mil.


Apyx Medical Cash Flow from Operations Historical Data

The historical data trend for Apyx Medical's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apyx Medical Cash Flow from Operations Chart

Apyx Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.48 -16.07 -10.45 -20.28 -5.25

Apyx Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.88 -4.85 3.70 -2.21 -6.34

Apyx Medical Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Apyx Medical's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Apyx Medical's Cash Flow from Operations for the quarter that ended in Mar. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apyx Medical  (NAS:APYX) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Apyx Medical's net income from continuing operations for the three months ended in Mar. 2024 was $-7.59 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Apyx Medical's depreciation, depletion and amortization for the three months ended in Mar. 2024 was $0.16 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Apyx Medical's change in working capital for the three months ended in Mar. 2024 was $-0.32 Mil. It means Apyx Medical's working capital declined by $0.32 Mil from Dec. 2023 to Mar. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Apyx Medical's cash flow from deferred tax for the three months ended in Mar. 2024 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Apyx Medical's cash from discontinued operating Activities for the three months ended in Mar. 2024 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Apyx Medical's asset impairment charge for the three months ended in Mar. 2024 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Apyx Medical's stock based compensation for the three months ended in Mar. 2024 was $1.13 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Apyx Medical's cash flow from others for the three months ended in Mar. 2024 was $0.28 Mil.


Apyx Medical Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Apyx Medical's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Apyx Medical (Apyx Medical) Business Description

Traded in Other Exchanges
Address
5115 Ulmerton Road, Clearwater, FL, USA, 33760
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
Executives
Todd Hornsby officer: Executive Vice President 14321 HAWTHORNE DR., CARMEL IN 46033
Goodwin Charles D. Ii director, officer: Chief Executive Officer 5115 ULMERTON ROAD, CLEARWATER FL 33760
Wendy Lauren Levine director 75 KENMARE STREET, APT. 2D, NEW YORK NY 10012
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Tara Semb officer: Chief Financial Officer 5516 RIVERSIDE HEIGHTS WAY, RICHMOND VA 23225
Craig A. Swandal director 5115 ULMERTON ROAD, CLEARWATER FL 33760
Michael Geraghty director 1342 CHERRY HILL ROAD, MENDOTA HEIGHTS MN 55118
Lawrence Waldman director 5115 ULMERTON RD., CLEARWATER FL 33770
John C. Andres director 86 CAPRI LANE, CHATHAM MA 02633
Jay D. Ewers officer: Chief Financial Officer 4 MANHATTANVILLE ROAD, SUITE 106, PURCHASE NY 10577
J Robert Saron director, officer: President
Robert Gershon director, officer: Chief Executive Officer 5115 ULMERTON ROAD, CLEARWATER FL 33760
Mccarthy John J. Iii officer: Chief CommercializationOfficer 23 RINALDO ROAD, NORTHPORT NY 11768
Scott Richard Davidson director C/O GREAT POINT PARTNERS, LLC, 165 MASON STREET, GREENWICH CT 06830
Moshe Citronowicz officer: Vice President of Operations

Apyx Medical (Apyx Medical) Headlines

From GuruFocus

Chuck Royce Adds Apyx Medical Corp to Portfolio

By GuruFocus Research 01-24-2024